Evidence map›Paper›PMID 41113156›Full record

ArticleACS measurement science au2025

A One-Pot RT-LAMP Diagnostic Assay for SARS-CoV‑2 from Saliva Samples.

Andrea C Mora, Allison J Tierney, Alexandra K Sogn, Paul T Lawrence, Elizabeth Tzavaras, Mabi L Singh, Gustavo Mahn Arteaga, Fiorenzo G Omenetto, Athena Papas, Charles R Mace

Abstract read
In one paragraph

Article in ACS measurement science au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andrea C MoraDepartment of Chemistry, Tufts University, 62 Talbot Avenue, Medford, Massachusetts 02155, United States.
Allison J TierneyDepartment of Chemistry, Tufts University, 62 Talbot Avenue, Medford, Massachusetts 02155, United States.
Alexandra K SognDepartment of Chemistry, Tufts University, 62 Talbot Avenue, Medford, Massachusetts 02155, United States.
Paul T LawrenceDepartment of Chemistry, Tufts University, 62 Talbot Avenue, Medford, Massachusetts 02155, United States.
Elizabeth TzavarasSchool of Dental Medicine, Tufts University, 1 Kneeland Street, Boston, Massachusetts 02111, United States.
Mabi L SinghSchool of Dental Medicine, Tufts University, 1 Kneeland Street, Boston, Massachusetts 02111, United States.
Gustavo Mahn ArteagaSchool of Dental Medicine, Tufts University, 1 Kneeland Street, Boston, Massachusetts 02111, United States.
Fiorenzo G OmenettoDepartment of Biomedical Engineering, Tufts University, 4 Colby Street, Medford, Massachusetts 02155, United States.ORCID https://orcid.org/0000-0002-0327-853X
Athena PapasSchool of Dental Medicine, Tufts University, 1 Kneeland Street, Boston, Massachusetts 02111, United States.
Charles R MaceDepartment of Chemistry, Tufts University, 62 Talbot Avenue, Medford, Massachusetts 02155, United States.ORCID https://orcid.org/0000-0003-3410-5014

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Results of efforts to diagnose infections with SARS-CoV-2 using a sampling method that was less invasive than the nasopharyngeal swab led to the rapid adoption of anterior nasal swabs. Saliva was also shown to have potential as a sample matrix and, like anterior nasal swabs, could be obtained noninvasively (e.g., passive drool). However, due to its inherent complexity and heterogeneity across patient populations (e.g., presence of mucins and RNases), saliva was largely disregarded as point-of-care diagnostics were being developed and broadly implemented. For molecular diagnostic approaches (e.g., RT-PCR or RT-LAMP), these matrix effects from saliva could lead to undesirable false positives or false negatives. The opportunity to address these challenges by normalizing the performance of saliva could enable important applications of molecular tests, particularly at the point-of-care. Toward these goals, we developed a one-pot RT-LAMP assay for the colorimetric detection of SARS-CoV-2 from saliva samples. The assay is performed in five steps: (i) a patient collects a passive saliva sample, (ii) the sample is placed on a heat block for 10 min at 95 °C, (iii) the undiluted sample is added to the one-pot RT-LAMP assay, (iv) the RT-LAMP reaction tube is place on a heat block for 40 min at 65 °C, and, (v) immediately postamplification, the reaction tube is inverted to observe the colorimetric output. We demonstrated the clinical performance of our assay using a panel of 127 patient samples. Our assay had an overall accuracy of 98%, with a sensitivity of 88% and a specificity of 100%. These results indicate excellent diagnostic agreement with the gold standard, RT-PCR, and highlight the potential to improve the clinical utility of saliva for point-of-care (e.g., mobile clinics) testing of SARS-CoV-2 and other upper respiratory viruses and emerging pathogens.

Indexed as

diagnosticspoint-of-careRT-LAMPsalivaSARS-CoV-2

Identifiers

PMID41113156
PMCPMC12532060

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.